DNMT3A and acute lymphoblastic leukemia: Adjusted for all these factors, DNMT3A expression remained an independent prognostic factor for RFS of patients with B-ALL (HR = 36.824, 95% CI: 3.746 ~ 362.033, P = 0.002, Table 2).